Document:

exv10w18

EXHIBIT 10.18

     XXXXX INDICATES MATERIAL THAT WAS OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT WAS REQUESTED.
ALL SUCH OMITTED MATERIAL WAS FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT
TO RULE 24b-2 PROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

SUPPLEMENTAL LICENSE AGREEMENT

     This Supplemental License Agreement (“Supplemental License Agreement”), dated as of
March 30, 2007 (the “Commencement Date”), is by and among Purdue Pharma L.P., a Delaware limited
partnership, The P.F. Laboratories, Inc., a New Jersey corporation, Purdue Pharmaceuticals L.P., a
Delaware limited partnership (the foregoing are individually and collectively referred to as the
“Purdue Companies”), and IMPAX Laboratories, Inc., a Delaware corporation (“IMPAX”). The Purdue
Companies and IMPAX are sometimes referred to herein individually as a “Party” and collectively as
the “Parties.”

WITNESSETH:

     WHEREAS, the Purdue Companies are the owners of United States patent numbers 5,549,912,
5,508,042 and 5,656,295 (the “Purdue Patents”), relating to and protecting controlled-release
oxycodone products, including the product OxyContin®, a controlled-release oxycodone product; and

     WHEREAS, the Purdue Companies and IMPAX entered into a Settlement Agreement, dated as of March
30, 2007 (the “Settlement Agreement”), and a Patent License Agreement, dated as of March 30, 2007
(the “PLA”), pursuant to which IMPAX was granted (i) a license of limited duration under the Purdue
Patents to make, have made, use, offer to Sell, Sell and have Sold (as such terms are defined
below) a certain number of Bottles (as defined below) of the generic versions of OxyContin®
products specifically described in ANDA No. 76-318 and

 

 

ANDA No. 76-446, along with all amendments and supplements thereto (collectively referred to
herein as the “IMPAX ANDA”), and (ii) an option to request, among other things, that the Purdue
Companies enter into this Supplemental License Agreement; and

     WHEREAS, this is the Supplemental License Agreement referred to in Section 1(e) of the PLA.

     NOW THEREFORE, the Parties agree as follows:

     1. License Grant; Supplemental License Amount.

          (a) Grant of License. The Purdue Companies hereby grant to IMPAX, a non-exclusive,
royalty-free, non-transferable (except as provided in Sections 1(d) and 12 below) license of
limited duration under the Purdue Patents to make, have made, use, offer to Sell, Sell and have
Sold the number of bottles, each containing 100 tablets (“Bottles”), determined in accordance with
Section 1(e) below (the “Supplemental License Amount”), of the generic versions of OxyContin®
products specifically described in, and sold under, the IMPAX ANDA as approved as of the Signing
Date (the “IMPAX Product”) in and for the United States (the “Supplemental License”), during the
period (the “Supplemental License Period”) commencing at 12:01 a.m., New York City time, on the
Commencement Date and terminating at 11:59 p.m., New York City time, on the “Supplemental License
Termination Date” (as provided in Section 1(e) below).

          (b) The Bottles sold by IMPAX, DAVA, or any party acting on their respective behalves,
pursuant to the Supplemental License shall be allocated according to dosage strength such that the
quantity of Bottles Sold of each dosage strength shall not vary by
more than twelve and one half percent (12.5%) from the number of Bottles set forth next to each dosage strength in Schedule 1
hereto; provided that, such variations, in the aggregate, may not

2

 

increase the Supplemental License Amount or increase the aggregate number of labeled kilograms
of oxycodone hydrochloride in the Bottles Sold pursuant to this
Supplemental License above 349 kilograms per 100,000 Bottles Sold.

          (c) Immediately upon the occurrence of the Supplemental License Termination Date all
solicitations for sale of IMPAX Product, offers to sell IMPAX Product, sales of IMPAX Product and
shipments of IMPAX Product into interstate commerce for commercial sale in the United States under
the Supplemental License shall cease as set forth in Section 2 hereof. Nothing herein shall
prohibit IMPAX from making, having made, using, selling, or offering for sale, any IMPAX Product
after the Terminal Date and subject to the provisions of the Settlement Documents.

          (d) IMPAX shall have no right to sublicense the license rights granted herein except to grant
only the limited, non-transferable right to Sell, offer to Sell and distribute IMPAX Product
permitted to be Sold hereunder to DAVA under the terms and conditions of this Supplemental License
Agreement until the Supplemental License Termination Date. Except as expressly granted herein, no
other right, written or oral license or sublicense, covenant not to sue, waiver or release of
future infringement or other written or oral authorization is granted or implied by this
Supplemental License Agreement. The Purdue Companies reserve all rights not expressly granted
herein, including the right to sue for patent infringement for sales that are not permitted
pursuant to the Supplemental License, except to the extent such suit is prohibited by Section 8(b)
hereof. For the avoidance of any doubt, nothing herein shall preclude the Purdue Companies, for
themselves or through a third party acting on their behalf, from soliciting offers for sale,
offering for sale, selling, shipping or causing to be shipped a Generic NDA Equivalent (as defined
in the PLA).

3

 

          (e) Supplemental License Amount and Supplemental License Termination Date.

          (i) The “Supplemental License Amount” shall mean the sum of the following amounts;

          (1)
250,000 Bottles; plus

          (2)
if at any time during the period which is fewer than 30 calendar days
immediately prior to the Commencement Date Mallinckrodt Inc., a
Delaware corporation or any of its Affiliates
(“Mallinckrodt”), sells and ships any Mallinckrodt Generic
Product (as defined below) into interstate
commerce for commercial sale to the Trade (as defined below) (that is not an
Affiliate of Mallinckrodt) in the United States and intended for subsequent immediate
distribution for patient use, then an additional 100,000 Bottles; plus

          (3)
if at any time during the period which is 30 or more calendar days
but fewer than 60 calendar days immediately prior to the Commencement
Date Mallinckrodt sells and ships any Mallinckrodt Generic Product into
interstate commerce for commercial sale to the Trade (that is not an Affiliate of
Mallinckrodt) in the United States and intended for subsequent immediate distribution for
patient use, then an additional 50,000 Bottles; plus

          (4)
if at any time during the period which is 60 or more calendar days
but fewer than 90 calendar days immediately prior to the Commencement
Date Mallinckrodt sells and ships any Mallinckrodt Generic Product into
interstate commerce for commercial sale to the Trade (that is not an Affiliate of
Mallinckrodt) in the United States and intended for subsequent immediate distribution for
patient use, then an additional 50,000 Bottles; plus

4

 

          (5) provided that IMPAX used its commercially reasonable efforts to sell the
License Amount during the License period under the PLA, in the event IMPAX sells
fewer than 523,000 Bottles from March 1, 2007 through the License Termination Date,
the number of Bottles equal to the difference between (A) 523,000 Bottles and (B) the
number of Bottles Sold by IMPAX, DAVA or any parties acting on their respective
behalves from March 1, 2007 through the License Termination Date, but in no event
will such amount exceed 150,000 Bottles; plus

          (6)
in the event (A) the Purdue Companies engage in the promotion, marketing or shipment of the Product, either by themselves or through a third party
distributor or licensee, during the period beginning on the Signing Date and ending on the Commencement Date, or (B) Mallinckrodt sells and ships during the period commencing on the
Signing Date and ending on the License Termination Date any Mallinckrodt Generic Product into interstate
commerce for commercial sale to the Trade (that is not an Affiliate
of Mallinckrodt) in the
United States and intended for subsequent immediate distribution for patient use
pursuant to a license granted by any of the Purdue Companies, in the case of either
(A) or (B) but not both, then an additional 100,000 Bottles.

For the avoidance of doubt, the Supplemental License Amount (a) is the maximum number of Bottles
permitted to be sold hereunder and all sales of the IMPAX Product must immediately cease no later
than the Supplemental License Termination Date regardless of whether the amount of Bottles actually
sold during the Supplemental License Period is less than the Supplemental License Amount and (b)
will not exceed 700,000 Bottles.

5

 

          (ii) The “Supplemental License Termination Date” shall be:

          (1) if the Supplemental License Amount is 250,000 Bottles, or if the Supplemental
License Amount is equal to 250,000 Bottles plus only one or both of the additional
amounts specified in clauses (i)(5) or (i)(6)(B) of the definition thereof, then
11:59 p.m., New York City time on January 29, 2008; provided,
however, that if this clause (1) applies and the Supplemental License Amount
also includes the additional amount specified in clause (i)(6)(A), then 11:59 p.m.,
New York City time on February 12, 2008; or

          (2) if the Supplemental License Amount includes one of the additional amounts
specified in clauses (i)(2) through (i)(4) of the definition thereof, then 11:59
p.m., New York City time on February 29, 2008; provided, however,
that if this clause (2) applies and the Supplemental License amount includes one of
the additional amounts specified in clauses (i)(5) or (i)(6)(A), then 11:59 p.m.,
New York City time on March 14, 2008;

provided, however, that if this Supplemental License Agreement is terminated
pursuant to Section 10 hereof prior to the dates set forth in (1) or (2) above, then the
Supplemental License Termination Date shall be the effective date of such termination.

          (iii) For purposes of this Supplemental License Agreement, the following terms have the
following meanings:

“Branded Product” means OxyContin® (oxycodone hydrochloride controlled-release) tablets, under NDA
number 20-553, together with all amendments and supplements thereto.

6

 

“Mallinckrodt
Generic Product means any 10 mg, 20 mg, 40 mg or
80 mg (i) AB rated generic version of the Branded Product
or (ii) any Product, that is sold or distributed
in the United States by Mallinckrodt.

“Product” means, except when used in “Branded Product” and “IMPAX Product”, any of the authorized
generic versions of 10 mg, 20 mg, 40 mg and 80 mg OxyContin® (oxycodone hydrochloride
controlled-release) tablets, under NDA number 20-553, together with all amendments and supplements
thereto and as marketed by the Purdue Companies as of the Signing Date.

“Trade” means wholesalers, chains, distributors, retailers, pharmacies, mail order pharmacies or
any other classes of trade that participate in the distribution or sale of pharmaceutical products.

          (iv) For purposes of this Section 1, the terms “Sell”, “Selling” or “Sold” mean selling
and shipping by IMPAX, DAVA, or any other party acting on their respective behalves to a
third party bona fide purchaser for commercial sale. For the avoidance of any doubt, sales
and shipments of Bottles by IMPAX to DAVA for subsequent selling and shipping to a third
party bona fide purchaser for commercial sale under a sublicense validly granted by IMPAX to
DAVA under Section 1(d) shall be permitted and shall be excluded for purposes of determining
the Bottles Sold hereunder.

          (v) Each Party will inform the other Party in writing within five (5) business days of
becoming aware of the fact that Mallinckrodt has sold and shipped any
Mallinckrodt Generic Product into interstate
commerce for commercial sale to the Trade (that is not an Affiliate of Mallinckrodt) in the United
States and intended for subsequent immediate distribution for patient use. The Purdue
Companies will inform IMPAX in writing within five (5) business days of entering into an
agreement with any third party, the effect of

7

 

which may result in additional Bottles being included within the Supplemental License
Amount.

     2. Effective Date and Supplemental License Termination Date. (a) The provisions of
this Supplemental License Agreement shall become effective on the Commencement Date. This
Supplemental License Agreement and all rights granted to IMPAX under this Supplemental License
Agreement (including any permitted sublicense thereof) will terminate on the Supplemental License
Termination Date. Without limiting the foregoing, from and after the Supplemental License
Termination Date until the Terminal Date, IMPAX will not, directly or indirectly, make, have made,
use, sell or offer to sell, import or distribute, or authorize, permit or solicit others to make,
use, have made, use, sell or offer to sell, import or distribute, or indemnify others regarding or
participate in the profits of others arising from the sale of, any controlled-release oxycodone
product that (i) is covered by the IMPAX ANDA or (ii) otherwise infringes any of the claims of any
of the Purdue Patents, including without limitation any sales or shipments from IMPAX to DAVA;
provided, however, that this sentence shall not be deemed to be breached in connection with any
IMPAX Product that is shipped to a bona fide purchaser for commercial sale by IMPAX or DAVA, as
permitted under this Supplemental License Agreement, prior to the Supplemental License Termination
Date. From and after the Supplemental License Termination Date until the Terminal Date, IMPAX shall
prohibit DAVA or any licensee, distributor, or any other party acting in a similar capacity to
DAVA, from soliciting offers for, offering to sell, selling, distributing, shipping, or causing to
be shipped, IMPAX Product into interstate commerce for commercial sale in the United States;
provided, however, that this sentence shall not be deemed to be breached in connection with any
IMPAX Product that is shipped by DAVA to a bona fide third party purchaser for commercial sale, as

8

 

permitted under this Supplemental License Agreement, prior to the Supplemental License
Termination Date. Promptly after the Supplemental License Termination Date, IMPAX shall destroy any
inventories of the IMPAX Product remaining in its possession or control, or in the possession or
control of any licensee, distributor or any other party acting in a similar capacity on the
Supplemental License Termination Date; provided, however, that IMPAX shall not be so obligated to
destroy such inventories in the event the Terminal Date occurs prior to the Supplemental License
Termination Date. Following the Supplemental License Termination Date, IMPAX shall deliver to the
Purdue Companies certificates from the Chief Financial Officer of IMPAX or any other executive
officer of IMPAX certifying (I) that IMPAX ceased, directly or indirectly, shipping, making, having
made, using, selling, offering to sell, importing, distributing, or indemnifying others regarding
or participating in the profits of others arising from the sale of any controlled-release oxycodone
product specified in clause (i) and (ii) herein (and has instructed DAVA to cease soliciting offers
for, offering to sell, selling, distributing, shipping or causing to be shipped) IMPAX Product into
interstate commerce for commercial sale in the United States on or before the Supplemental License
Termination Date, (II) the number of Bottles of IMPAX Product in each dosage strength sold by IMPAX
from the Commencement Date to the Supplemental License Termination Date, (III) that all inventories
of IMPAX Product remaining on the Supplemental License Termination Date have been destroyed (unless
IMPAX is not so obligated because the Terminal Date has occurred prior to the Supplemental License
Termination Date), (IV) that no sales resulting in sales above the Supplemental License Amount were
made by IMPAX between the Commencement Date and the Supplemental License Termination Date and (V)
that it has requested a certificate from DAVA and any party acting on IMPAX’s or DAVA’s behalf
making the certifications referred to in clauses (II) through (V)

9

 

above with respect to DAVA or such party. The certifications referred to in clause (I) above
shall be delivered two (2) business days following the Supplemental License Termination Date and
the certifications referred to in clauses (II)-(V) above shall be delivered within ten (10)
calendar days following the Supplemental License Termination Date. The certifications of DAVA and
any other party acting on IMPAX’s or DAVA’s behalf shall be delivered as soon as possible following
the Supplemental License Termination Date.

          (b) IMPAX acknowledges and agrees that IMPAX’s violation or breach of this Supplemental
License Agreement would cause the Purdue Companies to suffer substantial damages and irreparable
harm that could not adequately be remedied by an action at law. Accordingly, IMPAX agrees that the
Purdue Companies will be entitled, without limitation, to specific performance or preliminary or
permanent injunctive relief without the requirement of posting a bond in any action, hearing,
litigation or suit for violation or breach of this Supplemental License Agreement, such rights and
remedies being in addition to all other rights and remedies available to the Purdue Companies at
law, in equity or otherwise, and IMPAX will not assert in opposition to the Purdue Companies’
request for any equitable relief that the Purdue Companies have an adequate remedy at law. IMPAX
hereby waives and agrees not to raise or assert as a defense or counterclaim in any action brought
by the Purdue Companies to enforce IMPAX’s obligations hereunder, any contention of
non-infringement, invalidity or unenforceability of the Purdue Patents, or invalidity or
unenforceability of the ‘331 Patent, or any contention under Federal or state antitrust or unfair
competition laws; provided, however, that Impax shall not be prohibited from providing evidence
that the XXXXX. In addition to the foregoing rights and reservations, should IMPAX or DAVA (or any
other party acting on their respective behalves) ship any IMPAX Product into interstate commerce
for commercial sale in

10

 

the United States in excess of the Supplemental License Amount or after the Supplemental
License Termination Date but prior to the Terminal Date (in either case, “Excess Sales”), the
Purdue Companies shall have the right to receive, and IMPAX agrees promptly to pay the Purdue
Companies (without any waiver or offset by the Purdue Companies of any right to further damages) an
amount equal to $XXXXX; provided, however, that the XXXXX payable shall be
increased by a percentage equal to the amount of any announced percentage increase in XXXXX by the Purdue Companies subsequent to the
Signing Date. If, and only if, IMPAX has not complied with Section 11 (which shall not, for the
avoidance of doubt, affect the liability of IMPAX to make payments to the Purdue Companies in
respect of Excess Sales under this Section 2(b)), any breach of the provisions of this Section 2 by
DAVA or any licensee, distributor, or any other party acting in a similar capacity to DAVA shall be
deemed to be a breach by IMPAX of this Supplemental License Agreement.

          (c) If any of the certificates of the Chief Financial Officer of IMPAX (or any other executive
officer of IMPAX, if applicable) referred to in Section 2(a) hereof is not delivered to the Purdue
Companies in a timely manner, the Purdue Companies shall have, as their sole remedy for such
failure to deliver in a timely manner (as opposed to any noncompliance with any of the other
requirements of this Supplemental License Agreement), the right to engage a CPA Firm to conduct an
audit of IMPAX for the purposes of confirming that no sales of IMPAX Product resulted in Excess
Sales. Upon request by the Purdue Companies, IMPAX shall use its best efforts to exercise its audit
rights to conduct an audit of DAVA for the purposes of confirming that no sales of IMPAX Product
resulted in Excess Sales and that no sales of IMPAX Product occurred between the License
Termination Date and the Commencement Date. The CPA Firm shall be given access to and shall be permitted to examine and
copy such books and records of IMPAX, and to the extent permitted by DAVA, of DAVA, as it shall
request upon seven (7) business days’ notice having been given by the Purdue Companies and at all
reasonable times on business days for the purpose of reporting to the Parties that no sales of
IMPAX Product resulted in Excess Sales and that no sales of IMPAX Product occurred between the
License Termination Date and the

11

 

Commencement Date. Prior to any such examination taking place, the
CPA Firm shall commit to IMPAX and, to the extent the CPA Firm is afforded access to DAVA’s books
and records, DAVA, to keeping all information and data contained in such books and records,
strictly confidential and shall not disclose such information or copies of such books and records
to any third person, including the Purdue Companies, but shall use the same only for the purpose of
the reviews and/or calculations which the CPA Firm needs to perform in order to confirm that no
sales of IMPAX Product resulted in Excess Sales and that no sales of IMPAX Product occurred between
the License Termination Date and the Commencement Date. Notwithstanding the foregoing, if the CPA
Firm determines that sales of IMPAX Product resulted in Excess Sales or that sales of IMPAX Product
occurred between the License Termination Date and the Commencement Date, then the Purdue Companies
shall be entitled to receive a full written report of the CPA Firm with respect to its findings.
The determination by the CPA Firm following such audit shall be final and binding on the Parties;
provided, however, that IMPAX shall have the right, prior to such determination becoming binding on
the Parties, to make a presentation to the CPA Firm (which presentation shall be completed in one
(1) business day) to ensure such CPA Firm has adequate information to make its determination;
provided further that, the Purdue Companies may be present at such presentation and may make a
presentation to the CPA Firm following the IMPAX presentation.

12

 

If the report of the CPA Firm shows that sales of IMPAX Product resulted in Excess Sales or
that sales of IMPAX Product occurred between the License Termination Date and the Commencement
Date, IMPAX shall pay to the Purdue Companies (i) the amount specified in Section 2(b) and (ii) the
fees and expenses of the CPA Firm. If the CPA Firm reports that no such sales resulted in Excess
Sales and that no sales of IMPAX Product occurred between the License Termination Date and the
Commencement Date, the Purdue Companies shall pay the fees and expenses of the CPA Firm. IMPAX
shall cooperate with and shall use its best efforts to cause DAVA and its Affiliates to cooperate
with the CPA Firm in conducting such audit, including, without limitation, by providing sales
records relating to their sale of IMPAX Product.

          (d) During the Supplemental License Period, the Purdue Companies will use their commercially
reasonable efforts to assist IMPAX with respect to its submission of applications to the Drug
Enforcement Administration for quota allocations of oxycodone hydrochloride for use in
manufacturing the IMPAX Product under the Supplemental License, including providing information
about the Settlement Agreement and this Supplemental License Agreement relevant to such
applications by IMPAX.

          (e) The Supplemental License and all rights granted to IMPAX under the Supplemental License
may be terminated immediately by the Purdue Companies by notice to IMPAX if IMPAX (i) fails to
comply with any of the terms or provisions of this Supplemental License Agreement, the Settlement
Agreement or the PLA, (ii) has solicited offers for, offered to sell, sold, shipped or caused to be
shipped, IMPAX Product into interstate commerce for commercial sale in the United States, including
without limitation any sales or shipments among IMPAX and its Affiliates between the License
Termination Date and the Commencement Date or (iii) directly or
indirectly encourages Mallinckrodt to commence Selling (as defined in
Section 1(e)(iv) hereof) any Mallinckrodt Generic Product at any time.

13

 

     3. Food and Drug Administration. (a) Pursuant to 21 C.F.R. § 314.94(a)(12)(v), and
within 10 business days after the Commencement Date, IMPAX shall submit to the FDA, with a copy to
the Purdue Companies, a statement that IMPAX has been granted a license with respect to the Purdue
Patents with respect to the IMPAX Product, pursuant to the terms of this Supplemental License
Agreement.

          (b) Pursuant to 21 C.F.R. § 314.94(a)(12)(viii)(A), and within 10 business days of the
Supplemental License Termination Date, IMPAX shall submit to the FDA, with a copy to the Purdue
Companies, an amendment to IMPAX’s certifications in the IMPAX ANDA with respect to the Purdue
Patents, changing those certifications to certifications under 21 C.F.R. § 314.94(a)(12)(i)(A)(3)
and requesting that the FDA promptly change the IMPAX ANDA approval from an effective approval to a
tentative approval. In the event the Terminal Date (as defined in the Settlement Agreement) has
occurred prior to the date upon which IMPAX would otherwise be required to amend, pursuant to the
terms of this Section 3(b), IMPAX’s certifications in the IMPAX ANDA, then IMPAX shall not be
required to amend such certifications with respect to the IMPAX Product. From and after the
Terminal Date, nothing herein will prohibit IMPAX from filing or maintaining with respect to the
IMPAX Product a certification, including but not limited to a certification based on invalidity or
unenforceability pursuant to 21 U.S.C. § 355(j)(2)(A)(vii)(IV) and 21 C.F.R. §
314.94(a)(12)(i)(A)(4); provided, however, if there is a vacatur,
reversal or settlement of the type referred to in paragraph 19(x) or
(y) of the Settlement Agreement then within ten (10) days of the
issuance of such reversal or vacatur or within ten (10) days after
being notified in writing by the Purdue Companies of such settlement,
IMPAX shall submit to the FDA, with a copy to the Purdue Companies,
an amendment to IMPAX’s certifications and requests to the FDA
specified in this Section 3(b).

     4. Registration. IMPAX will be responsible for, and will bear all costs involved in
respect of, the registration of the IMPAX Product with any governmental regulatory agencies.

14

 

     5. WARRANTY DISCLAIMER. EXCEPT AS EXPRESSLY SET FORTH IN THIS SUPPLEMENTAL LICENSE
AGREEMENT, THE PLA OR IN THE SETTLEMENT AGREEMENT, NEITHER PARTY NOR THEIR AFFILIATES MAKES ANY
REPRESENTATIONS OR EXTENDS ANY WARRANTIES OF ANY KIND, EITHER EXPRESS OR IMPLIED, INCLUDING ANY
EXPRESS OR IMPLIED WARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, OR
NON-INFRINGEMENT, INCLUDING WITHOUT LIMITATION (1) FOR THE PURDUE COMPANIES, WITH RESPECT TO THE
PURDUE PATENTS OR ANY LICENSE GRANTED BY ANY OF THE PURDUE COMPANIES HEREUNDER, OR (2) ANY
MATERIALS OR INFORMATION PROVIDED BY SUCH PARTY OR ANY OF ITS AFFILIATES UNDER THIS SUPPLEMENTAL
LICENSE AGREEMENT, THE PLA OR THE SETTLEMENT AGREEMENT, OR (3) WITH RESPECT TO ANY PRODUCTS OR
SERVICES OF EITHER PARTY HERETO OR THEIR AFFILIATES. FURTHERMORE, UNLESS EXPRESSLY STATED IN THIS
SUPPLEMENTAL LICENSE AGREEMENT, THE PLA OR IN THE SETTLEMENT AGREEMENT, NOTHING IN THIS
SUPPLEMENTAL LICENSE AGREEMENT, THE PLA OR THE SETTLEMENT AGREEMENT SHALL BE CONSTRUED AS A
WARRANTY THAT ANY PATENT, THE PRACTICE OF ANY INVENTION CLAIMED IN ANY PATENT OR OTHER PROPRIETARY
RIGHTS INCLUDED IN THE PURDUE PATENTS OR ANY LICENSE GRANTED BY ANY OF THE PURDUE COMPANIES DO NOT,
OR THE MAKING, HAVING MADE, USING, SELLING, OFFERING FOR SALE OR IMPORTING OF IMPAX PRODUCTS BY
IMPAX DOES NOT INFRINGE ANY PATENT RIGHTS OR OTHER INTELLECTUAL PROPERTY RIGHTS OF ANY THIRD PARTY
WHO IS NOT AN AFFILIATE OF THE PURDUE COMPANIES. IT IS

15

 

HEREBY AGREED AND ACKNOWLEDGED BY IMPAX THAT THE PURDUE COMPANIES ARE GIVING NO GUARANTEE OR
WARRANTY, EXPRESS OR IMPLIED, TO IMPAX IN RELATION TO THE SAFETY OR THERAPEUTIC EFFECTIVENESS OF
THE IMPAX PRODUCT. FURTHER, IMPAX WILL NOT OWE ANY SUCH GUARANTEE OR WARRANTY TO ANY THIRD PARTIES
ON BEHALF OF THE PURDUE COMPANIES.

     6. Bankruptcy. The Supplemental License is, and shall otherwise be deemed to be, for
purposes of Section 365(n) of Title XI of the Bankruptcy Code, a license of rights to “intellectual
property” as defined in Section 101(56) of the Bankruptcy Code.

     7. Indemnification. (a) IMPAX shall defend, indemnify and hold harmless the Purdue
Companies, their Affiliates and the respective owners, directors, officers, agents and employees of
each of them (collectively, the “Purdue Parties”), from and against any and all expenses, demands,
liabilities, damages or money judgments (“Losses”) incurred by or rendered against the Purdue
Parties resulting from (i) any claim, action or proceeding by any third party arising out of the
making, use, offer for sale or sale of the IMPAX Product or any products previously made, used or
sold under the IMPAX ANDA, (ii) any claim, action or proceeding by any third party arising out of
any material breach by IMPAX of any of its representations, warranties, covenants or agreements
made under this Supplemental License Agreement, and (iii) any breach by IMPAX of the third and
fourth sentences of Section 2(a) of this Supplemental License Agreement; provided, however, that
IMPAX will not be liable to indemnify the Purdue Parties for any Losses of the Purdue Parties to
the extent such Losses were caused by (x) the negligence or willful misconduct or wrongdoing of the
Purdue Parties or (y) any material breach by the Purdue Parties of their representations,
warranties, covenants or agreements under this

16

 

Supplemental License Agreement and provided, further, that IMPAX’s maximum liability for
claims made (other than claims based on willful misconduct) by the Purdue Companies under Section
7(a)(ii) with respect to claims made by Teva or Endo and for claims made (other than claims based on willful
misconduct) by the Purdue Companies under Section 7(a)(iii), shall be limited to the greater of (A)
IMPAX’s aggregate gross margin from the sale of IMPAX Product
after the Signing Date and (B) $0.06 per milligram of labeled
oxycodone hydrochloride sold by IMPAX after the Signing Date and such
per milligram rate  shall be increased by a percentage equal to the amount of any
announced percentage increase in the price of the wholesale
acquisition cost of the Branded Product by the Purdue Companies subsequent to the Signing Date (the greater of such amounts, the “Aggregate
Gross Margin”), determined in accordance with United States generally accepted accounting
principles, consistently applied (and derived from IMPAX’s audited financial statements to the
extent possible), without duplication for any amounts paid to the Purdue Companies by IMPAX
pursuant to the limitation on liability provided for in the proviso to Section 7(a) of the PLA. In
the event that the Purdue Companies object to a determination made by IMPAX as to the Aggregate
Gross Margin in connection with a claim for indemnification made by the Purdue Companies hereunder,
the Purdue Companies will have the right to engage a CPA Firm to conduct an audit of IMPAX for the
purposes of confirming the Aggregate Gross Margin on substantially the same basis as in Section
2(c) hereof. The determination by the CPA Firm following such audit of Aggregate Gross Margin shall
be final and binding on the Parties; provided, however, that IMPAX shall have the right, prior to
such determination becoming binding upon the Parties, to make a presentation to the CPA Firm (which
presentation shall be completed in one (1) business day) to ensure such CPA Firm has adequate
information to make its determination; provided further that, the Purdue Companies may be present
at such presentation and may make a presentation to the CPA Firm following the IMPAX presentation.

17

 

          (b) The Purdue Companies shall defend, indemnify and hold harmless IMPAX, its Affiliates, and
the respective directors, officers, agents and employees of each of them (together, the “IMPAX
Parties”), from and against any and all Losses incurred by or rendered against the IMPAX Parties
resulting from (i) any claim, action or proceeding by any third party arising out of the sale by
the Purdue Companies of their controlled-release oxycodone product, including the product
OxyContin® and (ii) any claim, action or proceeding by any third party arising out of the Purdue
Companies’ material breach of any of their representations, warranties, covenants or agreements
made under this Supplemental License Agreement; provided, however, that the Purdue Companies will
not be liable to indemnify IMPAX for any Losses of IMPAX to the extent such Losses were caused by:
(x) the negligence or willful misconduct or wrongdoing of IMPAX or (y) any material breach by IMPAX
of its representations, warranties, covenants or agreements under this Supplemental License
Agreement. The provisions of this Section 7 shall not apply to any claims made by either Party or
by third parties under Federal or state antitrust or unfair competition laws.

     8. Purdue Companies’ Representations and Warranties; Covenant Not to Sue.

          (a) The Purdue Companies hereby represent and warrant as of the date hereof that: (i) each of
them has all necessary partnership or corporate, as applicable, power and authority to execute and
deliver this Supplemental License Agreement and to perform its obligations hereunder, and that the
execution, delivery and performance of this Supplemental License Agreement have been duly and
validly authorized by each of them; (ii) upon execution and delivery of this Supplemental License
Agreement by each of the Purdue Companies, this Supplemental License Agreement shall constitute the
legal, valid and binding agreement of each of them, enforceable against each of them in accordance
with its terms, subject to bankruptcy,

18

 

insolvency, reorganization, moratorium or other similar laws affecting the enforceability of
creditors’ rights generally and other general equitable principles which may limit the right to
obtain certain remedies; (iii) neither the execution, delivery and performance of this Supplemental
License Agreement nor the consummation or performance of this Supplemental License Agreement by the
Purdue Companies shall contravene, conflict with or result in any material violation or material
breach, as the case may be, of any law applicable to the Purdue Patents or any material contract to
which the Purdue Companies are a party; (iv) the Purdue Companies, their Affiliates and any
purchaser acquiring the Purdue Patents in compliance with the Settlement Documents, collectively
own all right, title and interest in and to each and every patent and/or patent application within
the Purdue U.S. Patent Family, and have not granted or otherwise transferred to any third party any
right to enforce any patent or patent applications included in the Purdue U.S. Patent Family, or
any right to practice any patent or patent application included in the Purdue U.S. Patent Family
that would conflict with the Supplemental License granted to IMPAX hereunder; (v) as of the Signing
Date, the licenses granted to XXXXX, respectively, are the only licenses or
options to license to the Purdue Patents granted by the Purdue Companies for the sale in the United
States of any 10 mg, 20 mg, 40 mg or 80 mg controlled-release oxycodone product that is (A) an AB
rated generic version of OxyContin® as described in NDA No. 20-553, together with all amendments
and supplements thereto or (B) an authorized generic approved pursuant to NDA No. 20-553, together
with all amendments and supplements thereto, and (vi) as of the Signing Date, to its knowledge,
Purdue had not received any notice of certification pursuant to 21 C.F.R § 314.94(a)(12)(i)(A)(4)
for any AB rated generic version of Oxycontin® as described in NDA No. 20-553, together with all

19

 

amendments
and supplements thereto from any third party other than Teva, Endo,
Mallinckrodt, KV Pharmaceutical Company and Actavis Totowa LLC or any
of their Affiliates. The Purdue Companies
also represent and warrant to IMPAX that any violation or breach of this Supplemental License
Agreement by IMPAX may cause the Purdue Companies to suffer substantial damages and irreparable
harm, including causing the Purdue Companies to be in violation or breach of, or severely
disadvantaged under, certain material agreements the Purdue Companies have entered into with third
parties, provided however, that the Purdue Companies acknowledge and agree that IMPAX has not been
provided a copy of such agreements nor an opportunity to review such agreements.

          (b) The Purdue Companies hereby covenant that neither they, nor any of their Affiliates will
sue, assert any claim or counterclaim against or otherwise participate in any action or proceeding
in the United States against IMPAX or its Affiliates claiming that the manufacture, use, sale,
offer for sale or importation of IMPAX Product pursuant to the Supplemental License, between the
Commencement Date and the Supplemental License Termination Date, infringes any patents owned,
licensed or controlled by the Purdue Companies or their Affiliates. Moreover, if and only if (1)
IMPAX does not breach Section 2(a) hereof, (2) XXXXX, and (3) IMPAX manufactures, uses, sells,
offers for sale or imports XXXXX thereafter, then the Purdue Companies hereby covenant that neither
they nor any of their Affiliates will sue, assert any counterclaim against or otherwise participate
in any action or proceeding against IMPAX or its Affiliates in the United States claiming that the
manufacture, use, sale, offer for sale or importation of XXXXX by virtue of paragraph 5(a)(B) of
the Settlement Agreement; provided, however, XXXXX. These covenants not to sue shall be
non-transferable (except as provided in Section 12 of this Supplemental License Agreement). Nothing
in this Section shall be interpreted

20

 

to prohibit the Purdue Companies from (i) suing, asserting any claim or counterclaim against
or otherwise participating in any action or proceeding against IMPAX with respect to any
formulations of oxycodone (other than the activities permitted pursuant to the Supplemental License
or other than the covenants granted in the first and second sentences of this Section 8(b)), or
(ii) enforcing this Supplemental License Agreement, the Settlement Agreement, the PLA or the
Consent Judgment. Notwithstanding any provision herein to the contrary, this Section does not apply
to, negate, or in any way limit any legal rights which the Purdue Companies may have relating in
any manner to claims regarding any patents against owners, holders, licensees or beneficiaries of
an ANDA (other than the manufacture, use, sale, offer for sale or importation of IMPAX Product
under clause (i) of the immediately preceding sentence of this Section 8(b)) approved by, or
submitted before or after the date of this Supplemental License Agreement to, the FDA for a
controlled-release oxycodone product that is an AB rated generic version of OxyContin® (oxycodone
hydrochloride controlled-release) Tablets under NDA No. 20-553, together with all amendments and
supplements thereto, regardless of whether such ANDA owner, holder, licensee or beneficiary is or
would otherwise be a manufacturer, supplier, importer, distributor, purchaser or user of the IMPAX
Product. The Purdue Companies further acknowledge that (1) the appropriate remedy for breach of
this Section 8(b) by the Purdue Companies is immediate dismissal, with prejudice of any patent
infringement action brought in breach of this Section 8(b); (2) time is of the essence in
dismissing any action brought in breach of this Section 8(b); and (3) that any available form of
expedited relief to have the dismissal granted and/or considered on appeal, including but not
limited to, a motion for hearing on shortened time, shall be appropriate in the event any of the
Purdue Companies brings an action in violation of this Section 8(b). The Purdue Companies further
agree not to oppose, directly or

21

 

indirectly, any motion to dismiss an action brought in breach of this Section 8(b) and not to
oppose any request for expedited ruling on such motion to dismiss.

          (c) The Purdue Companies hereby covenant that between the Commencement Date and the
Supplemental License Termination Date neither they, nor any of their Affiliates, will file, assist
(directly or indirectly) in the filing of, cause any other person (directly or indirectly) to file,
participate (directly or indirectly) in, or otherwise assist (directly or indirectly) a citizens' petition under 21 CFR 10.30, 10.33 or 10.35 requesting
agency action inconsistent with the Supplemental License;
provided that IMPAX has been in full compliance with the provisions of the fourth, fifth and sixth
sentences of Section 2(a) of the PLA. The Purdue Companies further acknowledge that Impax would
suffer substantial and irreparable harm from their breach of this covenant, that Impax would not
have an adequate remedy at law for such breach, and that a temporary restraining order, preliminary
injunction, and/or permanent injunction requiring withdrawal of such citizens' petition would be an appropriate remedy for such
breach.

     9. IMPAX’s Representations and Warranties.

          (a) IMPAX hereby represents and warrants as of the date hereof that: (i) it has all necessary
corporate power and authority to execute and deliver this Supplemental License Agreement and to
perform its obligations hereunder, and that the execution, delivery and performance of this
Supplemental License Agreement have been duly and validly authorized by it; (ii) upon execution and
delivery of this Supplemental License Agreement by IMPAX, this Supplemental License Agreement shall
constitute the legal, valid and binding agreement of IMPAX, enforceable against it in accordance
with its terms, subject to bankruptcy, insolvency, reorganization, moratorium or other similar laws
affecting the enforceability of creditors’ rights generally and other general equitable principles
which may limit the right to obtain certain remedies; (iii) neither the execution, delivery and
performance by IMPAX of this Supplemental

22

 

License Agreement nor the consummation or performance of this Supplemental License Agreement
by IMPAX shall contravene, conflict with or result in any material violation or material breach, as
the case may be, of any law applicable to IMPAX or any material contract to which IMPAX is a party;
(iv) no party other than IMPAX and DAVA is authorized to ship items from IMPAX’s warehouse; and (v)
IMPAX has not solicited offers for, offered to sell, sold, shipped or caused to be shipped IMPAX
Product into interstate commerce for commercial sale in the United States between the License
Termination Date and the Commencement Date.

     10. Termination. In the event of a material breach by IMPAX of this Supplemental
License Agreement or the Settlement Agreement, the Purdue Companies will have the right to
terminate this Supplemental License Agreement upon written notice to IMPAX, such termination to
take effect immediately upon the delivery of such notice to IMPAX.

     11. DAVA Breach Event. Notwithstanding anything to the contrary contained in this
Supplemental License Agreement (except for liability in respect of Excess Sales in Section 2(b)
hereof), including without limitation the last sentence of Section 2(b) hereof, IMPAX shall not be
deemed to have breached this Supplemental License Agreement to the extent that such breach has
resulted solely from the actions (or inactions) of DAVA under the DAVA Supply Agreement that were
not directly or indirectly taken (or not taken) at the direction of IMPAX, or in any way suggested,
encouraged or expressly or tacitly approved of, authorized, waived or released by IMPAX (any such
event, a “DAVA Breach Event”), provided that IMPAX shall have complied with each of the following:

          (i) Within two days of the Commencement Date, IMPAX shall have delivered a written
notice to DAVA and DDN/Obergfel Pharmaceutical Logistics (“DDN”), in a form reasonably
acceptable to the Purdue Companies, notifying such

23

 

persons of the Supplemental License Termination Date, that such persons will be
prohibited from selling, offering for sale, making customer solicitations or shipping IMPAX
Product from and after such date, that any rights granted to DAVA under Section 1(d) will
have expired, and, with respect to DAVA only, of IMPAX’s intention to pursue all available
legal and equitable remedies against DAVA to the extent that DAVA takes any such actions
from and after such date, including the sale, offer for sale, distribution or shipment of
IMPAX Product.

          (ii) Upon the earlier of (A) any time during the period commencing on the 5th business
day preceding the Supplemental License Termination Date and ending on the 2nd business day
preceding the Supplemental License Termination Date and (B) if this Supplemental License
Agreement is terminated by the Purdue Companies under Section 10 hereof, within two business
days of receipt of a written request from the Purdue Companies after the Supplemental
License Termination Date, IMPAX shall have delivered a written notice to DAVA and DDN in the
same form as the notice provided under clause (i) above, notifying such persons of the
Supplemental License Termination Date, that such persons will be prohibited from selling,
offering for sale, making customer solicitations or shipping IMPAX Product from and after
such date, that any rights granted to DAVA under Section 1(d) will have expired, and, with
respect to DAVA only, of IMPAX’s intention to pursue all available legal and equitable
remedies against DAVA to the extent that DAVA takes any such actions from and after such
date, including the sale, offer for sale, distribution or shipment of IMPAX Product.

          (iii) IMPAX shall have used its best efforts to cause DAVA to deliver the
certifications required by Section 2(a) hereof.

24

 

          (iv) If the Supplemental License Termination Date shall have occurred, IMPAX shall have
delivered a written notice to DAVA within two business days thereafter requesting that any
IMPAX Product then in DAVA’s possession or control promptly be returned to IMPAX, at IMPAX’s
expense.

          (v) IMPAX shall forward copies of the notices referred to in clauses (i), (ii) and (iv)
above to the Purdue Companies in the manner provided in Section 16 within two business days
of the sending of each such notice.

          (vi) If a DAVA Breach Event shall have occurred, IMPAX shall pursue any and all legal
and equitable remedies it may have against DAVA in connection with the facts and
circumstances giving rise to such event, and shall allow the Purdue Companies to participate
in any action or claim that it makes and/or asserts against DAVA in relation thereto at
IMPAX’s expense (including any expense incurred by the Purdue Companies for the retention of
its own counsel in connection with such matter). Any recoveries made against DAVA in
accordance with this Section 11 shall be for the benefit of, and be promptly paid by IMPAX
to, the Purdue Companies.

          (vii) IMPAX shall have monitored DAVA’s inventory levels of IMPAX Product prior to the
Supplemental License Termination Date as reported to IMPAX under and in a manner consistent
with the DAVA License Agreement and via any other lawful method reasonably available to
IMPAX, and shall have taken steps reasonably calculated to ensure, based on such
information, that IMPAX Product is not supplied to DAVA in an amount that is reasonably
anticipated to have resulted in Excess Sales, and to minimize the inventory of IMPAX Product
in DAVA’s possession or control as of the Supplemental License Termination Date.

25

 

     12. No Assignment. This Supplemental License Agreement is binding upon and shall
inure to the benefit of each Party hereto and each of its successors and permitted assigns. IMPAX
may not assign (by way of merger, acquisition, statute, operation of law or otherwise) this
Supplemental License Agreement (an “Assignment”) without the prior written consent of the Purdue
Companies which may be withheld in the Purdue Companies’ sole discretion; provided, however, that
the Purdue Companies’ consent shall not be required if such Assignment is part of the transfer of
all or substantially all of IMPAX’s assets or all of the equity or capital stock of IMPAX; provided
that such assignee is bound by and subject to the Settlement Agreement. Any Assignment, attempted
Assignment or assignment of the rights granted hereunder, by IMPAX, in contravention of the
provisions of this Section 12 shall be void and shall have no force or effect In the event that any
of the Purdue Companies (or any of their respective successors and assigns) sells or assigns (other
than in connection with the grant of a security interest) any of the Purdue Patents to any other
person or entity, such person or entity shall agree to assume the obligations of such Purdue
Company under this Supplemental License Agreement in writing as a condition to such acquisition.

     13. Entire Agreement. This Supplemental License Agreement, along with the PLA, the
Settlement Agreement and the documents referred to herein and therein, set forth the entire
agreement and understanding among the Parties hereto as to the subject matter hereof and supersede
all other documents, oral consents or understandings, if any, made between the Purdue Companies and
IMPAX (excluding any agreements or stipulations endorsed by court order) before the Commencement
Date with respect to the subject matter hereof. None of the terms of this Supplemental License
Agreement shall be amended or modified except in a writing signed by each of the Parties hereto. To
the extent there is an inconsistency between any provisions of

26

 

this Supplemental License Agreement and the Settlement Agreement, the provisions of the
Settlement Agreement shall govern. The Parties acknowledge that there have been a number of drafts
of this Supplemental License Agreement exchanged between them prior to the Parties’ agreement on
the final version of the Supplemental License Agreement which has been executed by them. The
Parties expressly agree that all such prior drafts have been superseded by this executed
Supplemental License Agreement and shall not be used in any dispute between the Parties as evidence
with respect to interpreting the meaning of any provision of this Supplemental License Agreement.

     14. Enforceability. Any term or provision of this Supplemental License Agreement
which is invalid or unenforceable in any jurisdiction shall, as to that jurisdiction, be
ineffective to the extent of such invalidity or unenforceability, without rendering invalid or
unenforceable the remaining terms and provisions of this Supplemental License Agreement in such
jurisdiction or in any other jurisdiction.

     15. Governing Law. This Supplemental License Agreement, and the rights and
obligations created hereunder, shall be governed by and interpreted according to the substantive
laws of the State of New York without regard to its choice of law or conflicts of law principles.

     16. Notices. Any notice required under this Supplemental License Agreement shall be
in writing and shall be given (and shall be deemed to be duly given upon receipt) by delivery in
person, by facsimile or by registered or certified mail (postage prepaid, return receipt requested)
to the respective Parties at the following addresses (or at such other address for a Party as shall
be specified by like notice):

If to any of the Purdue Companies:

Purdue Pharma L.P.

One Stamford Forum

201 Tresser Boulevard

27

 

Stamford, CT 06901-3431

Attn: Howard R. Udell

Executive Vice President

Chief Legal Officer

Fax No.: (203) 588-6204

with a copy to:

Chadbourne & Parke LLP

30 Rockefeller Plaza

New York, NY 10112

Attn: Stuart D. Baker

Fax No.: (212) 489-7130

If to IMPAX:

IMPAX Laboratories, Inc.

30831 Huntwood Avenue

Hayward, CA 94544

Attn: Chief Executive Officer

Fax No.: (510) 471-1595

with a copy to:

IMPAX Laboratories, Inc.

30831 Huntwood Avenue

Hayward, CA 94544

Attn: Legal Department

Fax No.: (510) 476-2092

     17. Effect of Waiver. A waiver by any Party of any term or condition of this
Supplemental License Agreement in any one instance shall not be deemed or construed to be a waiver
of such term or condition for any other instance in the future (whether similar or dissimilar) or
of any subsequent breach hereof. All rights, remedies, undertakings, obligations and agreements
contained in this Supplemental License Agreement shall be cumulative and none of them shall be a
limitation of any other remedy, right, undertaking, obligation or agreement of any of the Parties.

     18. Legal Advice; Investigation. Each of the Parties agrees that it has received
independent legal advice from its attorneys with respect to the rights and asserted rights arising

28

 

out of this Supplemental License Agreement, the PLA and the Settlement Agreement. Each of the
Parties further agrees that it and its counsel have had adequate opportunity to make whatever
investigation or inquiry they may deem necessary or desirable in connection with the subject matter
of this Supplemental License Agreement, prior to the execution hereof.

     19. Counterparts. This Supplemental License Agreement may be executed in counterparts
(including by facsimile or other electronic transmission), and each fully executed counterpart
shall be deemed an original of this Supplemental License Agreement.

     20. Definitions. All capitalized terms used herein and not defined shall have the
meanings specified in the PLA or in the Settlement Agreement. The definitions of the terms herein
apply equally to the singular and plural of the terms defined. Whenever the context may require,
any pronoun will include the corresponding masculine, feminine and neuter forms. The words
“include”, “includes” and “including” will be deemed to be followed by the phrase “without
limitation.” Unless the context requires otherwise, (A) any definition of or reference to any
agreement, instrument or other document herein will be construed as referring to such agreement,
instrument or other document as from time to time amended, supplemented or otherwise modified
(subject to any restrictions on such amendments, supplements or modifications set forth herein or
therein) and (B) the words “herein,” “hereof” and “hereunder,” and words of similar import, will be
construed to refer to this Supplemental License Agreement in its entirety and not to any particular
provision hereof.

[remainder of this page intentionally left blank]

29

 

Supplemental License Agreement Signature Page

     IN WITNESS WHEREOF, each of the Parties has caused this Supplemental License Agreement to be
executed as of the date first written above by its duly authorized officer or agent.

	 	 	 	 	 
	PURDUE PHARMA L.P.

 	 	 
	By:  	Purdue Pharma Inc., its general partner
 	 	 
	 
	 	 	 
	By:  	/s/ Edward Mahoney 	 	 
	 	Name:  	Ed Mahoney 	 	 
	 	Title:  	EVP & CFO 	 	 
	 
	 
	THE P.F. LABORATORIES, INC.

 	 	 
	By:  	/s/ Edward Mahoney 	 	 
	 	Name:  	Ed Mahoney 	 	 
	 	Title:  	EVP & CFO 	 	 
	 
	 
	PURDUE PHARMACEUTICALS L.P.

 	 	 
	By:  	Purdue Pharma Inc., its general partner
 	 	 
	 
	 	 	 
	By:  	/s/ Edward Mahoney 	 	 
	 	Name:  	Ed Mahoney 	 	 
	 	Title:  	EVP & CFO 	 	 
	 
	 
	IMPAX LABORATORIES, INC.

 	 	 
	By:  	/s/ David S. Doll 	 	 
	 	Name:  	David S. Doll 	 	 
	 	Title:  	 	 	 

 

 

	 	 	 	 	 

Schedule 1

SUPPLEMENT LICENSE AMOUNT

(a)
250,000 Bottles

	 	 	 	 	 
	Description	 	Number of Bottles
	10 mg 100 ct
	 	47,500
	20 mg 100 ct
	 	82,500
	40 mg 100 ct
	 	75,000
	80 mg 100 ct
	 	45,000

(b)
300,000 Bottles

	 	 	 	 	 
	Description	 	Number of Bottles
	10 mg 100 ct
	 	57,000
	20 mg 100 ct
	 	99,000
	40 mg 100 ct
	 	90,000
	80 mg 100 ct
	 	54,000

(c)
350,000 Bottles

	 	 	 	 	 
	Description	 	Number of Bottles
	10 mg 100 ct
	 	66,500
	20 mg 100 ct
	 	115,500
	40 mg 100 ct
	 	105,000
	80 mg 100 ct
	 	63,000

(d)
400,000 Bottles

	 	 	 	 	 
	Description	 	Number of Bottles
	10 mg 100 ct
	 	76,000
	20 mg 100 ct
	 	132,000
	40 mg 100 ct
	 	120,000
	80 mg 100 ct
	 	72,000

(e)
450,000 Bottles

	 	 	 	 	 
	Description	 	Number of Bottles
	10 mg 100 ct
	 	85,500
	20 mg 100 ct
	 	148,500
	40 mg 100 ct
	 	135,000
	80 mg 100 ct
	 	81,000

 

 

(f) Additional Bottles

	 	 	 	 	 
	 	 	Percentage of Supplemental
	Description	 	License Amount
	10 mg 100 ct
	 	 	19	%
	20 mg 100 ct
	 	 	33	%
	40 mg 100 ct
	 	 	30	%
	80 mg 100 ct
	 	 	18	%

32exv10w19

EXHIBIT 10.19

     XXXXX INDICATES MATERIAL THAT WAS OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT WAS REQUESTED.
ALL SUCH OMITTED MATERIAL WAS FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT
TO RULE 24b-2 PROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

SUBLICENSE AGREEMENT

     This Sublicense Agreement (the “Agreement”), effective as of March 30, 2007 (the “Effective
Date”), is by and between DAVA Pharmaceuticals, Inc., a Delaware corporation (“DAVA”), and IMPAX
Laboratories, Inc., a Delaware corporation (“IMPAX”).

     WHEREAS, IMPAX and DAVA are parties to that certain Supply and Distribution Agreement dated as
of November 3, 2005, as amended to date (the “Supply Agreement”) by which IMPAX appointed DAVA as
its exclusive distributor of the Products in the Territory and agreed to supply the Products to
DAVA in accordance with the terms of the Supply Agreement.

     WHEREAS, the Supply Agreement provides that IMPAX may suspend its obligations with respect to
the supply of the Products under the Supply Agreement in the event of a settlement of litigation
regarding the Products with Purdue;

     WHEREAS, IMPAX has entered into a Settlement with Purdue (the “Purdue Settlement”), pursuant
to which (1) IMPAX admitted that its manufacture and sale of the Products infringe Purdue’s patents
and that said patents are valid and enforceable; (2) Purdue and IMPAX entered into a Patent License
Agreement dated March 30, 2007 (the “Patent License Agreement”), pursuant to which Purdue has
granted IMPAX a license to manufacture and sell, with a right to sublicense to DAVA the right to
sell, 523,000 bottles of the Product, from March 1, 2007 through June 14, 2007; and (2) IMPAX and
Purdue agreed to enter into a Supplemental License Agreement (the “Supplemental License Agreement”)
pursuant to which Purdue will grant IMPAX a license to manufacture and sell, with a right to
sublicense to DAVA the right to sell, at least 250,000 and not more
than 700,000 bottles of the Product
from on or about November 27, 2007 through the termination of such Supplemental License Agreement;
and

     WHEREAS, IMPAX desires to sublicense its license rights under the Patent License Agreement to
DAVA, and to agree to sublicense its license rights under the Supplemental License Agreement to
DAVA, all on the terms and conditions set forth in this Agreement;

     NOW, THEREFORE, for good and valuable consideration, the receipt of which is hereby
acknowledged, the parties hereto, intending to be legally bound, agree as follows:

1. DEFINITIONS.

     1.1
“Branded Product” means OxyContin® (oxycodone hydrochloride controlled-release) tablets,
under NDA number 20-553, together with all amendments and supplements thereto.

     1.2 “Distribution Fee” shall have the meaning set forth in Section 5 hereof.

 

 

     1.3 “Patent License Effective Date” shall mean March 30, 2007.

     1.4 “Patent License Termination Date” shall mean the earlier of (i) 11:59 p.m., New York City
time on June 14, 2007 and (ii) the date upon which the Patent License Agreement is terminated.

     1.5 “Supplemental License Effective Date” shall mean November 27, 2007, subject to change to
an earlier date by Purdue with IMPAX’s consent.

     1.6 “Supplemental License Period” shall mean the period between the Supplemental License
Effective Date and the Supplemental License Termination Date.

     1.7 “Supplemental License Termination Date” shall mean the earlier of (i) 11:59 p.m., New York
City time on January 29, 2008 as such time may be extended pursuant to the terms of the
Supplemental License Agreement and (ii) the date upon which the Supplemental License Agreement is
terminated.

     1.8 “Supply Resumption Date” shall mean the date, following the Supplemental License
Termination Date, on which IMPAX is permitted, by the terms of the Settlement or by virtue of the
expiration, invalidity or unenforceability of Purdue’s patents related to the Branded Product, to
resume manufacture and sale of the Product.

     1.9 Capitalized terms not otherwise defined herein shall have the meaning given to them in the
Supply Agreement.

2. SUPPLY.

     2.1 During the Term of this Agreement, the supply of Product by IMPAX to DAVA under the Supply
Agreement shall be subject to the terms of this Agreement. IMPAX’s obligation under the Supply
Agreement to supply Product to DAVA shall be suspended from the Patent License Termination Date
until the Supplemental License Effective Date and from the Supplemental License Termination Date
until the Supply Resumption Date.

3. PATENT SUBLICENSE.

     3.1 IMPAX hereby grants to DAVA an exclusive, royalty-free, non-transferable sublicense of
limited duration of IMPAX’s license rights granted under the Patent License Agreement (“Patent
Sublicense”) to offer to Sell, Sell and distribute not more than that number of bottles of the
Product each containing 100 tablets (“Bottles”) equal to
the difference between (i) 523,000 minus
(ii) the number of Bottles sold by DAVA from March 1, 2007 through March 29, 2007 (the “License
Amount”), allocated among dosage strengths as set forth in Section 3.2 below in the United States
during the period commencing on the Patent License Effective Date and terminating upon the Patent
License Termination Date. IMPAX shall use commercially reasonable efforts to manufacture 523,000
Bottles for Sale by DAVA during the period commencing March 1, 2007 and ending on the Patent
License Termination Date. The terms “Sell,” “Selling” or “Sold,” for purposes of Sections 3 and 4
of this Agreement, mean selling and shipping by DAVA or any party acting on its behalf to a
third-party bona fide purchaser for commercial sale.

2

 

     3.2 The Bottles Sold by DAVA from March 1, 2007 through the Patent License Termination Date
shall be allocated according to dosage strength such that the quantity of Bottles Sold of each
dosage strength shall not vary by more than twelve and one half percent (12.5%) from the number of
Bottles set forth next to each dosage strength on Schedule 1 hereto; provided, that
variations, in the aggregate, may not increase the License Amount or
increase the aggregate number of labeled kilograms of oxycodone
hydrochloride in the Bottles Sold pursuant to this Patent License
above 349 kilograms per 100,000 Bottles Sold.

     3.3 All rights granted to DAVA under the Patent Sublicense will terminate on the Patent
License Termination Date. From and after the Patent License Termination Date until the Supply
Resumption Date, except as otherwise expressly provided in Section 4 hereof, DAVA shall not solicit
offers for, offer to sell, sell, ship or cause to be shipped or distribute or indemnify others
regarding or participate in profits of others arising from the sale of the Products. Within ten
(10) Business Days following the License Termination Date, DAVA will deliver to IMPAX a certificate
of the Chief Financial Officer of DAVA certifying (i) the number of Bottles of each dosage strength
sold by DAVA from March 1, 2007 through the License Termination Date; (ii) that no sales resulting
in sales above the License Amount were made by DAVA prior to the License Termination Date; and
(iii) that all inventories of the Products in DAVA’s possession or control and remaining on the
Patent License Termination Date have been quarantined or returned to IMPAX. The foregoing
notwithstanding, DAVA shall not be in default of this Section 3.3 if, despite using its
commercially reasonable efforts, DAVA has not received sufficiently specific information from DDN
Pharmaceutical Logistics to provide the certification described in subsection (i) of the preceding
sentence within such 10 Business Days, in which case it shall provide such certification as soon as
it is in possession of such information.

     3.4 Should DAVA (or any other party acting on its behalf) ship any Products into interstate
commerce for commercial sale in the United States in excess of the Licensed Amount or after the
Patent License Termination Date but prior to the Supply Resumption Date except pursuant to Section
4 (in either case, “Excess Sales”), and to the extent that IMPAX is required under the Patent
License Agreement to pay Purdue such amount with respect to such Excess Sales, IMPAX shall have the
right to receive from DAVA, and DAVA agrees to promptly pay to IMPAX (without any waiver or offset
by IMPAX of any right to further damages), an amount equal to $XXXXX of Excess Sales sold, which is
the amount IMPAX would be required to pay Purdue under the Patent License Agreement; provided,
however, that the XXXXX payable by DAVA shall be increased by a percentage equal to the amount of
any announced percentage increase in the price of the wholesale acquisition cost of the Branded
Product by Purdue. If an independent certified public accounting firm (a “CPA Firm”) chosen by
Purdue under the Patent License Agreement conducts an audit of IMPAX for the purposes of confirming
that no sales of the Products resulted in Excess Sales, DAVA shall make its books and records
available at DAVA’s offices in Fort Lee, New Jersey for a period of no more than two (2) Business
Days to such CPA Firm upon seven (7) Business Days prior notice from IMPAX and at all reasonable
times on Business Days for the purpose of reporting to Purdue and IMPAX that no sales of the
Products resulted in Excess Sales. Prior to any such examination taking place, the CPA firm shall
commit in writing to DAVA, in an agreement of form and substance reasonably acceptable to DAVA, to
keep all information and data contained in such books and records strictly confidential and shall
not disclose such information or copies of such books and records to any third person, including
Purdue, but shall use the same only for the purpose of the reviews and/or calculations that the CPA
Firm needs to perform in order to confirm that no sales of the Products resulted in

3

 

Excess Sales. Notwithstanding the foregoing, if the CPA Firm determines that sales of the
Products resulted in Excess Sales, then Purdue shall be entitled to receive a full written report
from the CPA Firm with respect to the findings. If the CPA Firm report shows that sales by DAVA
resulted in Excess Sales, DAVA shall reimburse IMPAX for any amount IMPAX is required under the
Patent License Agreement to pay to Purdue for the fees and expenses of the CPA Firm.

4. SUPPLEMENTAL PATENT SUBLICENSE.

     4.1 Subject to IMPAX and Purdue having entered into the Supplemental License Agreement, IMPAX
hereby grants to DAVA an exclusive, royalty-free, non-transferable sublicense of limited duration
of Impax’s license rights granted under the Supplemental License Agreement (“Supplemental Patent
Sublicense”) to offer to Sell, Sell and distribute 250,000 Bottles plus such additional Bottles as
are determined pursuant to the Supplemental License Agreement (the “Supplemental License Amount”),
allocated among dosage strengths as set forth in Section 4.2 below in the United States during the
period commencing on the Supplemental License Effective Date and terminating upon the Supplemental
License Termination Date. IMPAX shall notify DAVA within one (1) Business Days of becoming aware of
(i) Bottles in excess of 250,000 being included within the Supplemental License Amount and (ii) any
change in the Supplemental License Effective Date and Supplemental License Termination Date.

     4.2 Notwithstanding anything to the contrary herein, if DAVA fails to comply with any
instruction from IMPAX to cease sales of the Products, which instruction is mandated by the terms
of the Purdue Settlement, the Patent License Agreement or the Supplemental License Agreement, then
the Supplemental Patent Sublicense shall automatically terminate and DAVA shall have no further
right to offer to Sell, Sell or distribute the Products, and shall have no right to any proceeds
from sales of the Products, until the Supply Resumption Date.

     4.3 The Bottles Sold by DAVA during the Supplemental License Period shall be allocated
according to dosage strength such that the quantity of Bottles Sold of each dosage strength shall
not vary by more than twelve and one half percent (12.5%) from the number of Bottles set forth next
to each dosage strength on Schedule 2 hereto; provided, that variations, in the aggregate,
may not increase the Supplemental License Amount or increase the
aggregate number of labeled kilograms of oxycodone hydrochloride in
the Bottles Sold during the Supplemental License Period above
349 kilograms per 100,000 Bottles Sold.

     4.4 All rights granted to DAVA under the Supplemental Patent Sublicense will terminate on the
Supplemental License Termination Date. From and after the Supplemental License Termination Date
until the Supply Resumption Date, DAVA may not solicit offers for, offer to sell, sell, ship or
cause to be shipped or distribute or indemnify others regarding or participate in profits of others
arising from, the Products. Promptly after the Supplemental License Termination Date, DAVA shall
follow the instructions of IMPAX to return or destroy, at IMPAX’s sole cost and expense, all
inventories of the Products remaining in its possession or control, unless the Supply Resumption
Date occurs prior to the Supplemental License Termination Date. Within ten (10) Business Days
following the Supplemental License Termination Date, DAVA will deliver to IMPAX a certificate of
the Chief Financial Officer of DAVA certifying (i) the number of Bottles of each dosage strength
sold by DAVA during the Supplemental License Period; (ii) that all inventories of the Products
remaining in DAVA’s possession or control on the Supplemental License Termination Date have been
returned to

4

 

IMPAX or destroyed; and (iii) that no sales resulting in sales above the Supplemental License
Amount were made by DAVA during the Supplemental License Period. The foregoing notwithstanding,
DAVA shall not be in default of this Section 3.3 if, despite using its commercially reasonable
efforts, DAVA has not received sufficiently specific information from DDN Pharmaceutical Logistics
to provide the certification described in subsection (i) of the preceding sentence within such 10
Business Days, in which case it shall provide such certification as soon as it is in possession of
such information.

     4.5 Should DAVA (or any other party acting on its behalf) ship any Products into interstate
commerce for commercial sale in the United States in excess of the Supplemental License Amount or
after the Supplemental License Termination Date but prior to the Supply Resumption Date (in either
case, “Excess Sales”), and to the extent that IMPAX is required under its Supplemental License
Agreement with Purdue to pay Purdue such amount with respect to such Excess Sales, IMPAX shall have
the right to receive from DAVA, and DAVA agrees to promptly pay to IMPAX (without any waiver or
offset by IMPAX of any right to further damages), an amount equal to $XXXXX of Excess Sales sold,
which is the amount IMPAX would be required to pay Purdue under the Supplemental License Agreement;
provided, however, that the XXXXX payable by DAVA shall be increased by a percentage equal to the
amount of any announced percentage increase in the price of the wholesale acquisition cost of the
Branded Product by Purdue. If a CPA Firm chosen by Purdue and reasonably acceptable to IMPAX
conducts an audit of IMPAX for the purposes of confirming that no sales of the Products resulted in
Excess Sales, DAVA shall make its books and records available to such CPA firm at DAVA’s offices in
Fort Lee, New Jersey for a period of no more than two (2) Business Days upon seven (7) Business
Days prior notice from IMPAX and at all reasonable times on business days for the purpose of
reporting to Purdue and IMPAX that no sales of the Products resulted in Excess Sales. Prior to any
such examination taking place, the CPA firm shall commit in writing to DAVA, in an agreement of
form and substance reasonably acceptable to DAVA, to keep all information and data contained in
such books and records strictly confidential and shall not disclose such information or copies of
such books and records to any third person, including Purdue, but shall use the same only for the
purpose of the reviews and/or calculations which the CPA Firm needs to perform in order to confirm
that no sales of the Products resulted in Excess Sales. Notwithstanding the foregoing, if the CPA
Firm determines that sales of the Products resulted in Excess Sales, then Purdue shall be entitled
to receive a full written report from the CPA Firm with respect to the findings. If the CPA Firm
report shows that sales by DAVA resulted in Excess Sales, DAVA shall reimburse IMPAX for any amount
IMPAX is required under the Supplemental License Agreement to pay to Purdue for the fees and
expenses of the CPA Firm.

5. GROSS PROFIT SPLIT.

     5.1 The Gross Profit Split under Section 5.3 of the Supply Agreement shall be applicable only
to Product sales through the Patent License Termination Date and from and after the Supply
Resumption Date and shall not be applicable to Product sales during the Supplemental License
Period.

6. DISTRIBUTION FEE.

5

 

     6.1 For Products sold during the Supplemental License Period IMPAX shall pay DAVA XXXXX% of
Gross Margin (the “Distribution Fee”); provided,
however, that to the extent that fewer than 523,000 Bottles are sold from March 1, 2007 through the License Termination Date, the Distribution Fee
shall be equal to XXXXX% of Gross Margin. Gross Margin shall mean Net Sales minus Acquisition
Price.

7. TERMINATION.

     7.1 The term of this Agreement shall commence on the Effective Date and shall continue until
the sooner to occur of the (i) Supply Resumption Date and (ii) the termination of the Supply
Agreement (the “Term”).

8. REPRESENTATIONS, WARRANTIES AND COVENANTS.

     8.1 IMPAX represents that, as of the Effective Date: (i) the Patent License Agreement is in
full force and effect; (ii) subject to its compliance with the terms of the Patent License
Agreement, IMPAX has the right to enter into the Supplemental License Agreement; (iii) IMPAX is not
in default under the Patent License Agreement; (iv) IMPAX has the right and authority to enter into
this Agreement and to grant the sublicenses granted hereunder to DAVA; and (v) the terms of
Sections 3 and 4 hereof reflect, and are consistent in their entirety with, the terms of the Patent
License Agreement and the form of Supplemental License Agreement that IMPAX and Purdue have agreed
to enter into. If IMPAX receives any notice of default under either the Patent License Agreement or
under the Supplemental License Agreement, which in IMPAX’s reasonable judgment is likely to result
in the termination of either of those agreements, IMPAX will promptly notify DAVA.

     8.2 IMPAX represents and warrants that (i) prior to DAVA’s entering into the letter agreement
with IMPAX dated March 27, 2007 relating to the Purdue Settlement (the “Letter Agreement”), IMPAX
disclosed to DAVA all facts concerning the Settlement that were material to DAVA’s decision to
enter into the Letter Agreement and (ii) the Purdue Settlement includes no material changes or
additions to the Settlement terms described in the second paragraph of the Letter Agreement.

9. WARRANTY DISCLAIMER.

     9.1 EXCEPT AS EXPRESSLY SET FORTH HEREIN, IMPAX MAKES NO REPRESENTATIONS AND EXTENDS NO
WARRANTIES OF ANY KIND, EITHER EXPRESS OR IMPLIED, INCLUDING ANY EXPRESS OR IMPLIED WARRANTIES OF
MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE OR NON-INFRINGEMENT WITH RESPECT TO THE PURDUE
PATENTS OR ANY SUBLICENSE GRANTED BY IMPAX HEREUNDER. FURTHERMORE, UNLESS EXPRESSLY STATED HEREIN,
NOTHING HEREIN SHALL BE CONSTRUED AS A WARRANTY THAT ANY PURDUE PATENT, THE PRACTICE OF ANY
INVENTION CLAIMED IN ANY PURDUE PATENT OR OTHER PROPRIETARY RIGHTS INCLUDED IN THE PURDUE PATENTS
OR ANY SUBLICENSE GRANTED BY IMPAX HEREUNDER DO NOT, OR THE SELLING, OFFERING FOR SALE, OR
DISTRIBUTION OF THE PRODUCTS BY DAVA

6

 

DOES NOT, INFRINGE ANY PATENT RIGHTS OR OTHER INTELLECTUAL PROPERTY RIGHTS OF ANY THIRD PARTY
(OTHER THAN THOSE OF PURDUE).

10. INDEMNIFICATION.

     10.1 DAVA shall defend, indemnify and hold harmless IMPAX, its Affiliates and their respective
owners, directors, officers, agents and employees (together, the “IMPAX Parties”), from and against
any and all expenses, demands, liabilities, damages or money judgments incurred by or rendered
against the IMPAX Parties resulting from DAVA’s breach of any of its covenants or agreements made
under this Agreement.

     10.2 IMPAX shall defend, indemnify and hold harmless DAVA, its Affiliates and their respective
owners, directors, officers, agents and employees (together, the “DAVA Parties”), from and against
any and all expenses, demands, liabilities, damages or money judgments incurred by or rendered
against the DAVA Parties resulting from IMPAX’s breach of any of its covenants, representations,
warranties, or agreements made under this Agreement.

11. MISCELLANEOUS.

     11.1 Except as set forth herein, all other terms and conditions of the Supply Agreement remain
in full force and effect. In case of any inconsistency between the terms of this Agreement and the
Supply Agreement, the terms of this Agreement shall prevail.

     11.2 The validity and interpretation of this Amendment and the legal relations of the Parties
to it shall be governed by the internal laws, and not the law of conflicts, of the State of
Delaware. The parties acknowledge and agree not to contest that the courts of the State of Delaware
have personal jurisdiction over them with respect to any action that may be taken hereunder, and
venue shall lie in such courts as to any such action.

     11.3 This Agreement, together with each Schedule attached hereto, states the entire
understanding among the parties with respect to the subject matter hereof, and supersedes the
Letter Agreement.

     11.4 This Agreement may be signed in two counterparts, each of which shall be deemed an
original and both of which shall together constitute one agreement.

7

 

	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	DAVA PHARMACEUTICALS, INC.	 	 	 	IMPAX LABORATORIES, INC.	 	 
	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	By:	 	/s/ Lewis Tepper	 	 	 	By:	 	/s/ David S. Doll	 	 
	 	 	 	 	 	 	 	 	 	 	 
	 

	 	Printed Name:
	 	Lewis Tepper
	 	 	 	 	 	Printed Name:
	 	David S. Doll	 	 
	 

	 	Title:
	 	Senior Vice
President and
General Counsel
	 	 	 	 	 	Title:
	 	Executive Vice
President,
Commercial
Operations	 	 
	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	Date: August 8, 2007	 	 	 	Date: August 7, 2007	 	 

8

 

SCHEDULE 1

ALLOCATION AMONG DOSAGE STRENGTHS

DURING PATENT LICENSE PERIOD

	 	 	 
	Dosage Strength	 	Number of Bottles
	10 mg
	 	99,000
	20 mg
	 	173,000
	40 mg
	 	157,000
	80 mg
	 	94,000

9

 

SCHEDULE 2

ALLOCATION AMONG DOSAGE STRENGTHS

DURING SUPPLEMENTAL LICENSE PERIOD

(a)
250,000 Bottles

	 	 	 
	Dosage Strength	 	Number of Bottles
	 	 	 
	10 mg 100 ct
	 	47,500
	20 mg 100 ct
	 	82,500
	40 mg 100 ct
	 	75,000
	80 mg 100 ct
	 	45,000

(b)
300,000 Bottles

	 	 	 
	Dosage Strength	 	Number of Bottles
	 	 	 
	10 mg 100 ct
	 	57,000
	20 mg 100 ct
	 	99,000
	40 mg 100 ct
	 	90,000
	80 mg 100 ct
	 	54,000

(c)
350,000 Bottles

	 	 	 
	Dosage Strength	 	Number of Bottles
	 	 	 
	10 mg 100 ct
	 	66,500
	20 mg 100 ct
	 	115,500
	40 mg 100 ct
	 	105,000
	80 mg 100 ct
	 	63,000

(d)
400,000 Bottles

	 	 	 
	Dosage Strength	 	Number of Bottles
	 	 	 
	10 mg 100 ct
	 	76,000
	20 mg 100 ct
	 	132,000
	40 mg 100 ct
	 	120,000
	80 mg 100 ct
	 	72,000

10

 

(e)
450,000 Bottles

	 	 	 
	Dosage Strength	 	Number of Bottles
	 	 	 
	10 mg 100 ct
	 	85,500
	20 mg 100 ct
	 	148,500
	40 mg 100 ct
	 	135,000
	80 mg 100 ct
	 	81,000

(f) Additional Bottles

	 	 	 
	Dosage Strength	 	Percentage of Supplemental License Amount
	 	 	 
	10 mg 100 ct
	 	19%
	20 mg 100 ct
	 	33%
	40 mg 100 ct
	 	30%
	80 mg 100 ct
	 	18%

11

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00152-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00152-of-00352.parquet"}]]